Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Denver Health and Hospital Authority
• Collaborator: American Academy of Child Adolescent Psychiatry.
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Age 12-19

• Provided assent/consent

• attention-deficit hyperactivity disorder (ADHD) by Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS)

• Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV) checklist <=22

• At least one non-nicotine substance use disorder (SUD) by KSADS

• Plans to live locally for 4 months

• Willing to participate in cognitive behavioral therapy (CBT)

Exclusion Criteria:

• No mental illness that cannot be managed as an outpatient or without concurrent psychotropic medication

• No allergy to atomoxetine

• No narrow angle glaucoma

• No serious medical illness

• Not pregnant

• Not unwilling to use an effective form of contraception during the trial

• No SUD that cannot be managed as an outpatient or without concurrent psychotropic medication